drugset / Trial / NCT02172144
Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers
RandomizedCrossoverDouble-blindTreatment
Summary
Study to investigate the effect of BI 1744 CL on the QT/QTc interval of the ECG (electrocardiogram) in comparison to placebo
Timeline
- Start
- 2007-06
- Primary completion
- 2007-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Moxifloxacin | Small molecule | — | — |
| Subject | Olodaterol | Small molecule | 10 ug | Inhaled |
| Subject | Olodaterol | Small molecule | 20 ug | Inhaled |
| Subject | Olodaterol | Small molecule | 30 ug | Inhaled |
| Subject | Olodaterol | Small molecule | 50 ug | Inhaled |
Indications
No indication recorded.